• No results found

A review of frovatriptan for the treatment of menstrual migraine

N/A
N/A
Protected

Academic year: 2020

Share "A review of frovatriptan for the treatment of menstrual migraine"

Copied!
13
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Figure 1 Headache recurrence vs half-life for different triptans, after 2 hours.Notes: Copyright © 2003, John Wiley and Sons
Table 2 Clinical trials of frovatriptan for acute treatment of menstrual migraine: post hoc analyses of three placebo-controlled RCTs
Figure 2 Pain relief following treatment with frovatriptan versus almotriptan, rizatriptan, or zolmitriptan.Abbreviations: CI, confidence interval; df, degrees of freedom; M-H, Mantel-Haenszel.
Figure 3 Pain-free response following treatment with frovatriptan versus almotriptan, rizatriptan, or zolmitriptan.Abbreviations: CI, confidence interval; df, degrees of freedom; M-H, Mantel-Haenszel.
+3

References

Related documents

The prevalence of some cardiovascular risk factors such as smoking, hypercholesterolaemia, elevated blood glucose, and hypertension were lower in this rural

Floyd and Zemich (1991, quoted by Soleimani) studying effects of slow pace children on quality of marital relations and ability of parents in role paying stated that slow pace

20-24 In the present study, simple, selective and stable method using high performance liquid chromatography coupled with electro spray ionization single

Furthermore, different cancer types, stages, and differentiation grades may have unique miRNA expression profiles, which make miRNAs potent biomarkers for cancer di-

The aim of the study was to investigate the effects of interrupted synthesis of 5-HT and immobilization stress during different gestational period on brain serotonergic system of male

peter- sianum showed a selective inhibition of cyclooxygenase (COX)-1/COX-2 [ 5]. In Togo, the whole plant is re- ported to have antihypertensive effect and previous studies

Therefore, mutations in BRCA1 and BRCA2 genes are so effective in the increased risk for developing early-onset breast cancer and familial ovarian cancer, that mutations in these